APO Research
Talk to an analyst

APO RESEARCH · REPORT

Afatinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Afatinib Market Outlook and Growth Opportunities 2026

23 December 2025193 pages

Choose your research edition.

Industry ResearchAfatinib Industry Research Report 2026101 pages · $2,950 USDIndustry Growth & TrendsGlobal Afatinib Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal Afatinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Afatinib Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Afatinib Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Afatinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Afatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Afatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Afatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Afatinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Afatinib market include Boehringer Ingelheim, Beacon Pharma and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Afatinib market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Afatinib and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Afatinib revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Afatinib market.

Afatinib Segment by Company

Boehringer Ingelheim

Beacon Pharma

Hengrui Medicine

Afatinib Segment by Type

50mg Tables

40mg Tables

30mg Tables

25mg Tables

20mg Tables

Others

Afatinib Segment by Application

Drug Center

Hospital

Clinic

Others

Afatinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Afatinib status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Afatinib key companies, revenue, market share, and recent developments.

3. To split the Afatinib breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Afatinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Afatinib significant trends, drivers, influence factors in global and regions.

6. To analyze Afatinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Afatinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Afatinib industry.

Chapter 3: Detailed analysis of Afatinib company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Afatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Afatinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Afatinib Industry Trends Table 2. Afatinib Industry Drivers Table 3. Afatinib Industry Opportunities and Challenges Table 4. Afatinib Industry Restraints Table 5. Global Afatinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Afatinib Revenue Share by Company (2021-2026) Table 7. Global Afatinib Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Afatinib Key Company Manufacturing Base & Headquarters Table 9. Global Afatinib Company, Product Type & Application Table 10. Global Afatinib Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Afatinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 50mg Tables Table 15. Significant Companies of 40mg Tables Table 16. Significant Companies of 30mg Tables Table 17. Significant Companies of 25mg Tables Table 18. Significant Companies of 20mg Tables Table 19. Significant Companies of Others Table 20. Global Afatinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Afatinib Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Afatinib Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Afatinib Sales Value Share by Type (2021-2026) Table 24. Global Afatinib Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Drug Center Table 26. Significant Companies of Hospital Table 27. Significant Companies of Clinic Table 28. Significant Companies of Others Table 29. Global Afatinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Afatinib Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Afatinib Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Afatinib Sales Value Share by Application (2021-2026) Table 33. Global Afatinib Sales Value Share by Application (2027-2032) Table 34. Global Afatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Afatinib Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Afatinib Sales Value Share by Region (2021-2026) Table 37. Global Afatinib Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Afatinib Sales Value Share by Region (2027-2032) Table 39. Global Afatinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Afatinib Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Afatinib Sales Value Market Share by Country (2021-2026) Table 42. Global Afatinib Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Afatinib Sales Value Market Share by Country (2027-2032) Table 44. Boehringer Ingelheim Company Information Table 45. Boehringer Ingelheim Business Overview Table 46. Boehringer Ingelheim Afatinib Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Boehringer Ingelheim Afatinib Product Portfolio Table 48. Boehringer Ingelheim Recent Development Table 49. Beacon Pharma Company Information Table 50. Beacon Pharma Business Overview Table 51. Beacon Pharma Afatinib Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Beacon Pharma Afatinib Product Portfolio Table 53. Beacon Pharma Recent Development Table 54. Hengrui Medicine Company Information Table 55. Hengrui Medicine Business Overview Table 56. Hengrui Medicine Afatinib Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Hengrui Medicine Afatinib Product Portfolio Table 58. Hengrui Medicine Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. Afatinib Product Image Figure 2. Global Afatinib Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Afatinib Market Size (2021-2032) & (US$ Million) Figure 4. Global Afatinib Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 50mg Tables Image Figure 8. 40mg Tables Image Figure 9. 30mg Tables Image Figure 10. 25mg Tables Image Figure 11. 20mg Tables Image Figure 12. Others Image Figure 13. Global Afatinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Afatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Afatinib Sales Value Share by Type (2021-2032) Figure 16. Drug Center Image Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Afatinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Afatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Afatinib Sales Value Share by Application (2021-2032) Figure 23. Global Afatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Afatinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Afatinib Sales Value (2021-2032) & (US$ Million) Figure 26. North America Afatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Afatinib Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Afatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Afatinib Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Afatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Afatinib Sales Value (2021-2032) & (US$ Million) Figure 32. South America Afatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Afatinib Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Afatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Afatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Afatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Afatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg Tables
  • 40mg Tables
  • 30mg Tables
  • 25mg Tables
  • 20mg Tables
  • Others
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Boehringer Ingelheim
  • Beacon Pharma
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Afatinib Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Afatinib Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Afatinib Market Dynamics
  1. 2.1 Afatinib Industry Trends
  2. 2.2 Afatinib Industry Drivers
  3. 2.3 Afatinib Industry Opportunities and Challenges
  4. 2.4 Afatinib Industry Restraints
3 Afatinib Market by Company
  1. 3.1 Global Afatinib Company Revenue Ranking in 2025
  2. 3.2 Global Afatinib Revenue by Company (2021-2026)
  3. 3.3 Global Afatinib Company Ranking (2024-2026)
  4. 3.4 Global Afatinib Company Manufacturing Base and Headquarters
  5. 3.5 Global Afatinib Company Product Type and Application
  6. 3.6 Global Afatinib Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Afatinib Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Afatinib Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Afatinib Market by Type
  1. 4.1 Afatinib Type Introduction
  2. 4.1.1 50mg Tables
  3. 4.1.2 40mg Tables
  4. 4.1.3 30mg Tables
  5. 4.1.4 25mg Tables
  6. 4.1.5 20mg Tables
  7. 4.1.6 Others
  8. 4.2 Global Afatinib Sales Value by Type
  9. 4.2.1 Global Afatinib Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Afatinib Sales Value by Type (2021-2032)
  11. 4.2.3 Global Afatinib Sales Value Share by Type (2021-2032)
5 Afatinib Market by Application
  1. 5.1 Afatinib Application Introduction
  2. 5.1.1 Drug Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Afatinib Sales Value by Application
  7. 5.2.1 Global Afatinib Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Afatinib Sales Value by Application (2021-2032)
  9. 5.2.3 Global Afatinib Sales Value Share by Application (2021-2032)
6 Afatinib Regional Value Analysis
  1. 6.1 Global Afatinib Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Afatinib Sales Value by Region (2021-2032)
  3. 6.2.1 Global Afatinib Sales Value by Region: 2021-2026
  4. 6.2.2 Global Afatinib Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Afatinib Sales Value (2021-2032)
  7. 6.3.2 North America Afatinib Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Afatinib Sales Value (2021-2032)
  10. 6.4.2 Europe Afatinib Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Afatinib Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Afatinib Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Afatinib Sales Value (2021-2032)
  16. 6.6.2 South America Afatinib Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Afatinib Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Afatinib Sales Value Share by Country, 2025 VS 2032
7 Afatinib Country-level Value Analysis
  1. 7.1 Global Afatinib Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Afatinib Sales Value by Country (2021-2032)
  3. 7.2.1 Global Afatinib Sales Value by Country (2021-2026)
  4. 7.2.2 Global Afatinib Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Afatinib Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Afatinib Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Afatinib Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Afatinib Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Afatinib Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Afatinib Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Afatinib Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Afatinib Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Afatinib Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Afatinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Afatinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Afatinib Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Afatinib Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Afatinib Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Afatinib Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Afatinib Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Afatinib Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Afatinib Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Afatinib Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Afatinib Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Afatinib Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Afatinib Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Afatinib Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Afatinib Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Afatinib Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Afatinib Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Afatinib Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Afatinib Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Afatinib Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Afatinib Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Afatinib Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Afatinib Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Afatinib Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Afatinib Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Afatinib Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Afatinib Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Afatinib Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Afatinib Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Afatinib Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Afatinib Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Afatinib Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Afatinib Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Afatinib Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Afatinib Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Afatinib Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Afatinib Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Afatinib Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Afatinib Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Afatinib Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Afatinib Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Afatinib Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Afatinib Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Afatinib Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Afatinib Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Afatinib Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Afatinib Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Afatinib Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Afatinib Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Afatinib Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Afatinib Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Afatinib Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Afatinib Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Afatinib Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Afatinib Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Afatinib Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Afatinib Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Afatinib Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Afatinib Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Afatinib Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Afatinib Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Afatinib Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Afatinib Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Afatinib Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Afatinib Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Afatinib Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Afatinib Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Afatinib Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Afatinib Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Afatinib Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Afatinib Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Afatinib Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Afatinib Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Afatinib Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Afatinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Afatinib Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Afatinib Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Beacon Pharma
  8. 8.2.1 Beacon Pharma Company Information
  9. 8.2.2 Beacon Pharma Business Overview
  10. 8.2.3 Beacon Pharma Afatinib Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beacon Pharma Afatinib Product Portfolio
  12. 8.2.5 Beacon Pharma Recent Developments
  13. 8.3 Hengrui Medicine
  14. 8.3.1 Hengrui Medicine Company Information
  15. 8.3.2 Hengrui Medicine Business Overview
  16. 8.3.3 Hengrui Medicine Afatinib Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hengrui Medicine Afatinib Product Portfolio
  18. 8.3.5 Hengrui Medicine Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst